Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Section Details


INFORMATION

 
Issue Title
 
Vol 18, No 3 (2022) Academicians and Corresponding Members of the Russian Academy of Science (Division of Medical Sciences) Elected by the General Meeting of Members of the Russian Academy of Science in June 1-3, 2022 Abstract   PDF (Rus)
article Editorial
 
Vol 16, No 1 (2020) Report of the Editorial Board of the “Rational Pharmacotherapy in Cardiology” Journal about Work in 2019 Abstract   PDF (Rus)
E. K. Butina
 
Vol 16, No 1 (2020) Free medications for treating cardiovascular disease in non-beneficiary patients Abstract   PDF (Rus)
Article Editorial
 
Vol 15, No 6 (2019) Academicians and Corresponding Members of the Russian Academy of Science (Division of Medical Sciences) Elected by the General Meeting of Members of the Russian Academy of Science in November 14-15, 2019 Abstract   PDF (Rus)
Article Editorial
 
Vol 15, No 6 (2019) Index of the Papers Published in the “Rational Pharmacotherapy in Cardiology” Journal in 2019 Abstract   PDF (Rus)
Article Editorial
 
Vol 15, No 5 (2019) Findings Released from NAXOS Analysis. Pfizer Company Press Release Abstract   PDF (Rus)
article Editorial
 
Vol 15, No 4 (2019) According to the AUGUSTUS Trial Apixaban (Eliquis ® ) was Found to Be Safer than Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation with Acute Coronary Syndrome and/or Percutaneous Coronary Intervention Abstract   PDF (Rus)
Company Pfizer
 
Vol 15, No 1 (2019) Report of the Editorial Board of the “Rational Pharmacotherapy in Cardiology” Journal about Work in 2018 Abstract   PDF (Rus)
E. K. Butina
 
Vol 15, No 1 (2019) XIII Russian Scientific Conference with International Participation “Rehabilitation and Secondary Prevention in Cardiology” May 21-22, 2019, Nizhny Novgorod Abstract   PDF (Rus)
article Editorial
 
Vol 14, No 6 (2018) The Situation with Valsartan – Commentary of S.A. Boytsov, Chief Cardiologist of Ministry of Health of Russia for the Central, Urals, Siberian and Far Eastern Federal Districts Abstract   PDF (Eng)
artilce Editorial
 
Vol 14, No 6 (2018) Professor S.A. Shalnova Received the Scopus Awards Russia 2018 as One of the Most Cited Scientists of the Russian Federation in the Healthcare Category Abstract   PDF (Eng)
artilce Editorial
 
Vol 14, No 6 (2018) VIII International Forum of Cardiology and Internal Medicine, 27-29 March 2019, Moscow. Information letter Abstract   PDF (Eng)
artilce Editorial
 
Vol 14, No 6 (2018) The Results of Rivaroxaban Studies COMMANDER HF and MARINER Were Published. Bayer Company Press Release . Abstract   PDF (Eng)
artilce Editorial
 
Vol 14, No 5 (2018) Bayer registered a new indication for rivaroxaban for use in patients with coronary heart disease or peripheral artery disease in the European Union and USA Abstract   PDF (Rus)
Bayer Company Press Release
 
Vol 14, No 1 (2018) REPORT OF THE EDITORIAL BOARD OF THE “RATIONAL PHARMACOTHERAPY IN CARDIOLOGY” JOURNAL ABOUT WORK IN 2017 Abstract   PDF (Rus)
E. K. Butina
 
Vol 13, No 6 (2017) INDEX OF THE PAPERS PUBLISHED IN THE “RATIONAL PHARMACOTHERAPY IN CARDIOLOGY” JOURNAL IN 2017 Abstract   PDF (Rus)
article editotial
 
Vol 13, No 6 (2017) PREVALENCE OF HYPERURICEMIA AMONG PATIENTS WITH METABOLIC SYNDROME: RESULTS OF THE STUDY IN REAL CLINICAL PRACTICE Abstract   PDF (Rus)
D. V. Nebieridze, N. V. Dolgushina
 
Vol 13, No 5 (2017) RIVAROXABAN OF THE BAYER COMPANY SIGNIFICANTLY (BY 24%) REDUCES THE RISK OF STROKE, CARDIOVASCULAR DEATH AND MYOCARDIAL INFARCTION IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE OR PERIPHERAL ARTERIAL DISEASE Abstract   PDF (Rus)
статья Редакционная
 
Vol 13, No 2 (2017) RIVAROXABAN HAS DEMONSTRATED AN ADVANTAGE OVER ACETYLSALICYLIC ACID IN PREVENTING THE RECURRENCE OF VENOUS THROMBOEMBOLIC EVENTS IN THE EINSTEIN CHOICE STUDY Abstract   PDF (Rus)
. Editorial
 
Vol 13, No 1 (2017) REPORT ON ACTIVITY OF THE EDITORIAL BOARD OF “RATIONAL PHARMACOTHERAPY IN CARDIOLOGY” IN 2016 Abstract   PDF (Rus)
E. K. Butina
 
Vol 13, No 1 (2017) DATA OF THE RECENTLY PUBLISHED SWISS STUDY SWIVTER (THE SWISS VENOUS THROMBOEMBOLISM REGISTRY) DEMONSTRATE THE REPRODUCIBILITY OF THE RESULTS OF RANDOMIZED TRIALS IN REAL CLINICAL PRACTICE Abstract   PDF (Rus)
статья Редкционная
 
Vol 12, No 6 (2016) INDEX OF THE PAPERS PUBLISHED IN THE “RATIONAL PHARMACOTHERAPY IN CARDIOLOGY” JOURNAL IN 2016 Abstract   PDF (Rus)
article editorial
 
Vol 12, No 6 (2016) NEW DATA OF EXTENSIVE RESEARCH PROGRAM AND THE RESULTS OF STUDIES IN REAL CLINICAL PRACTICE FROM DIFFERENT COUNTRIES REAFFIRMED THE HIGH EFFICACY AND A FAVORABLE SAFETY PROFILE OF RIVAROXABAN (XARELTO®) FROM THE BAYER COMPANY PRESS RELEASE OF THE BAYER COMPANY Abstract   PDF (Rus)
article editorial
 
Vol 12, No 6 (2016) ALL-RUSSIAN SCIENTIFIC AND PRACTICAL CONFERENCE "NON-COMMUNICABLE DISEASES AND THE HEALTH OF THE POPULATION OF RUSSIA", MAY 16-18, 2017, MOSCOW INFORMATION LETTER Abstract   PDF (Rus)
article editorial
 
Vol 12, No 6 (2016) RAS ACADEMICIANS AND CORRESPONDING MEMBERS OF RAS ELECTED BY THE GENERAL MEETING OF MEMBERS OF RAS ON OCTOBER 27-28, 2016 BY DEPARTMENTS OF PHYSIOLOGY AND MEDICINE Abstract   PDF (Rus)
article editorial
 
Vol 12, No 5 (2016) II Interregional Conference of Cardiologists and Internists, Ulyanovsk, 5-6 December 2016 Information letter Abstract   PDF (Rus)
Editorial article
 
Vol 12, No 4 (2016) VI Caucasus scientific and educational conference of cardiology and internal medicine, 25-26 October, 2016. Information letter Abstract   PDF (Rus)
Article Editorial
 
Vol 12, No 4 (2016) New data from clinical practice again confirmed the high efficacy and a favorable safety profile of the drug Xarelto® in patients with atrial fibrillation (Press release of the company Bayer) Abstract   PDF (Rus)
Article Editorial
 
Vol 12, No 1 (2016) Report on activity of editorial board of “Rational Pharmacotherapy in Cardiology” in 2015 Abstract   PDF (Rus)
M. I. Smirnova
 
1 - 29 of 29 Items